Reprinted with the kind permission of Life Extension.
September 6 2017. In a review published on September 4, 2017 in the Journal of the American Geriatrics Society, researchers from the Mayo Clinic predicted that senolytic drugs that are the subject of experimental research have the potential to transform the treatment of disease by preventing or delaying chronic conditions as a group, rather than one at a time.
Senolytic agents target senescent cells, which have stopped dividing and release compounds that damage nearby cells. Senescent cell accumulation is associated with arthritis, cardiovascular disease, cancer, dementia, frailty and diabetes.
Recent research conducted by the Mayo Clinic, along with the Scripps Research Institute, confirmed that senolytic drugs clear senescent cells without affecting normal cells. A new screening platform and human cell assays identified and confirmed a novel category of these drugs, which are known as heat shock protein 90 (HSP90) inhibitors. The research was reported in Nature Communications.
“We’ve moved rapidly in the last few years, and it’s increasingly looking like senolytic drugs, including the recently discovered HSP90 inhibitors, are having an impact on a huge range of diseases,” commented James Kirkland, MD, PhD, who is the director of the Mayo Clinic’s Robert and Arlene Kogod Center on Aging. “We will need to continue to test whether there are more optimal drugs or drug combinations to broaden the range of senescent cell types targeted.”
“Our goal is to achieve the same success in humans as we have in preclinical animal models in efforts to prevent or delay the conditions associated with aging,” Dr Kirkland added.